Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced that the first patient has been enrolled in a pivotal, multicenter U.S. Phase II/III trial of AntiBKV, MTx’s antibody therapeutic that targets BK polyomavirus infection in renal transplant patients.
